Antihistamines for treatment of Long COVID
Phase 4
- Conditions
- Health Condition 1: B338- Other specified viral diseases
- Registration Number
- CTRI/2022/07/043679
- Lead Sponsor
- Dr Arjun M C
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 8
Inclusion Criteria
Adults diagnosed with COVID-19 and presenting with Long COVID symptoms after 3 months of COVID-19 diagnosis (Diagnosed with RTPCR or RAT only)
Exclusion Criteria
Pregnant and lactating women
Patients who are severely ill, bedridden or cannot follow up in hospital
Patients having Diagnosed Liver or kidney diseases
Those who do not consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the intensity of symptoms after intervention. At baseline the symptoms will be recorded using a Binary (Yes/No) symptoms grid and at follow-up the same symptoms reassessed for change (Identical, worse, better, absent). Outcome will be reported as proportion of people who experienced change in symptoms. <br/ ><br>Timepoint: All participants will be followed up for a period of 14 days from the date of enrolment. Follow-up will be done telephonically.
- Secondary Outcome Measures
Name Time Method Decrease in Chalder Fatigue scale score from baseline to follow-up <br/ ><br>Timepoint: All participants will be followed up for a period of 14 days from the date of enrolment. Follow-up will be done telephonically.